Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology

Trivioli "Slowly progressive anti-neutrophil cytoplasmic antibody-associated renal vasculitis: clinico-pathological characterization and outcome" Clin Kidney J (2021) 10.1093/ckj/sfaa139

[5]

van Daalen "Developments in the histopathological classification of ANCA-associated glomerulonephritis" Clin J Am Soc Nephrol (2020) 10.2215/cjn.14561119

[6]

Berden "Histopathologic classification of ANCA-associated glomerulonephritis" J Am Soc Nephrol (2010) 10.1681/asn.2010050477

[7]

Casal Moura "Kidney biopsy chronicity grading in antineutrophil cytoplasmic antibody-associated vasculitis" Nephrol Dial Transplant (2021)

[8]

Development and validation of a renal risk score in ANCA-associated glomerulonephritis

Silke R. Brix, Mercedes Noriega, Pierre Tennstedt et al.

Kidney International 2018 10.1016/j.kint.2018.07.020

[9]

Bate "The improved kidney risk score in ANCA-associated vasculitis for clinical practice and trials" J Am Soc Nephrol (2024) 10.1681/asn.0000000000000274

[10]

Hellmich "EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update" Ann Rheum Dis (2023) 10.1136/ard-2022-223764

[11]

Floege "Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA–Associated Vasculitis" Kidney Int (2024) 10.1016/j.kint.2023.10.009

[12]

Specks "Efficacy of remission-induction regimens for ANCA-associated vasculitis" N Engl J Med (2013) 10.1056/nejmoa1213277

[13]

Geetha "Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement" J Am Soc Nephrol (2015) 10.1681/asn.2014010046

[14]

Jones "Rituximab versus cyclophosphamide in ANCA-Associated Renal Vasculitis" N Engl J Med (2010) 10.1056/nejmoa0909169

[15]

Jones "Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial" Ann Rheum Dis (2015) 10.1136/annrheumdis-2014-206404

[16]

Casal Moura "Efficacy of rituximab and plasma exchange in antineutrophil cytoplasmic antibody–associated vasculitis with severe kidney disease" J Am Soc Nephrol (2020) 10.1681/asn.2019111197

[17]

Wallace "Comparative effectiveness of rituximab- versus cyclophosphamide-based remission induction strategies in antineutrophil cytoplasmic antibody-associated vasculitis for the risk of kidney failure and mortality" Arthritis Rheumatol (2023) 10.1002/art.42515

[18]

Predictive Factors of Renal Recovery and Progression to End-Stage Kidney Disease in Patients With Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis With Severe Kidney Disease

Marta Casal Moura, Dalia Zubidat, Marc Patricio Liebana et al.

Kidney International Reports 2024 10.1016/j.ekir.2024.02.1431

[19]

Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies

Richard Watts, Suzanne Lane, Thomas Hanslik et al.

Annals of the Rheumatic Diseases 2007 10.1136/ard.2006.054593

[20]

Modification and validation of the Birmingham Vasculitis Activity Score (version 3)

C Mukhtyar, R Lee, D Brown et al.

Annals of the Rheumatic Diseases 2009 10.1136/ard.2008.101279

[21]

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey, Lesley A. Stevens, Christopher H. Schmid et al.

Annals of Internal Medicine 2009 10.7326/0003-4819-150-9-200905050-00006

[22]

(2019)

[23]

Therneau (2000)

[24]

Kassambara "Survminer: drawing survival curves using “ggplot2”" R package version 0.4.9 (2021)

[25]

Heinze "logistf: Firth’s Bias-Reduced Logistic Regression" R package version 1.26.1 (2025)

[26]

Heinze "coxphf: cox Regression with Firth’s Penalized Likelihood" R package version 1.13.4 (2023)

[27]

mice: Multivariate Imputation by Chained Equations inR

Stef van Buuren, Karin Groothuis-Oudshoorn

Journal of Statistical Software 2011 10.18637/jss.v045.i03

[28]

White "Imputing missing covariate values for the Cox model" Stat Med (2009) 10.1002/sim.3618

[29]

Rubin (1987)

[30]

Miscellanea. Small-sample degrees of freedom with multiple imputation

J Barnard

Biometrika 1999 10.1093/biomet/86.4.948

[31]

Engesser "Immune profiling-based targeting of pathogenic T cells with ustekinumab in ANCA-associated glomerulonephritis" Nat Commun (2024) 10.1038/s41467-024-52525-w

[32]

Odler "The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial" Kidney Int (2025) 10.1016/j.kint.2024.11.029

[33]

Schmitt "Recovery of kidney function after acute kidney injury in the elderly: a systematic review and meta-analysis" Am J Kidney Dis (2008) 10.1053/j.ajkd.2008.03.005

[34]

Chang-Panesso "Acute kidney injury and aging" Pediatr Nephrol (2021) 10.1007/s00467-020-04849-0

[35]

McAdoo "Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis" Nephrol Dial Transplant (2019) 10.1093/ndt/gfx378

[36]

Sp "Long-term follow-up of a glucocorticoid minimizing regimen for the treatment of severe antineutrophil cytoplasmic autoantibody-associated vasculitis" Kidney Int Rep (2025) 10.1016/j.ekir.2025.03.009

[37]

Jayne "Avacopan for the treatment of ANCA-associated vasculitis" N Engl J Med (2021) 10.1056/nejmoa2023386

[38]

Cortazar "Renal recovery for patients with ANCA-associated vasculitis and low eGFR in the ADVOCATE trial of avacopan" Kidney Int Rep (2023) 10.1016/j.ekir.2023.01.039

Metrics

2

Citations

38

References

Details

Published: Mar 01, 2026
Vol/Issue: 11(3)
Pages: 103776
License: View

Authors

Rutherford Appleton Laboratory, Oxfordshire, UK

School of Medicine and Surgery, University of Milano-Bicocca , Monza , Italy; Istituto Auxologico Italiano, IRCCS , Milan , Italy

Renal Division, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan , Milan ,

Medicine, University of Cambridge School of Clinical Medicine, Cambridge, UK

F

Federico Alberici

Funding

AstraZeneca

National Institute on Handicapped Research

Otsuka Pharmaceutical

Meath Foundation Award: RG122/2021

UK Kidney Association

California State Library

Cite This Article

Martina Uzzo, Federica Mescia, Jennifer Scott, et al. (2026). Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology. Kidney International Reports, 11(3), 103776. https://doi.org/10.1016/j.ekir.2026.103776

Kidney Outcomes in ANCA-Glomerulonephritis According to Induction Immunosuppression and Histopathology

You May Also Like